: Monoacylglycerol lipase (MAGL) is the enzyme responsible for the metabolism of 2-arachidonoylglycerol in the brain and the hydrolysis of peripheral monoacylglycerols. Many studies demonstrated beneficial effects deriving from MAGL inhibition for neurodegenerative diseases, inflammatory pathologies, and cancer. MAGL expression is increased in invasive tumors, furnishing free fatty acids as pro-tumorigenic signals and for tumor cell growth. Here, a new class of benzylpiperidine-based MAGL inhibitors was synthesized, leading to the identification of 13, which showed potent reversible and selective MAGL inhibition. Associated with MAGL overexpression and the prognostic role in pancreatic cancer, derivative 13 showed antiproliferative activity and apoptosis induction, as well as the ability to reduce cell migration in primary pancreatic cancer cultures, and displayed a synergistic interaction with the chemotherapeutic drug gemcitabine. These results suggest that the class of benzylpiperidine-based MAGL inhibitors have potential as a new class of therapeutic agents and MAGL could play a role in pancreatic cancer.

Bononi, G., Di Stefano, M., Poli, G., Ortore, G., Meier, P., Masetto, F., et al. (2022). Reversible monoacylglycerol lipase inhibitors: discovery of a new class of benzylpiperidine derivatives. JOURNAL OF MEDICINAL CHEMISTRY, 65(10), 7118-7140-7140 [10.1021/acs.jmedchem.1c01806].

Reversible monoacylglycerol lipase inhibitors: discovery of a new class of benzylpiperidine derivatives

Di Stefano, Miriana
Membro del Collaboration Group
;
Vagaggini, Chiara;Brai, Annalaura;Dreassi, Elena;Valoti, Massimo;
2022-01-01

Abstract

: Monoacylglycerol lipase (MAGL) is the enzyme responsible for the metabolism of 2-arachidonoylglycerol in the brain and the hydrolysis of peripheral monoacylglycerols. Many studies demonstrated beneficial effects deriving from MAGL inhibition for neurodegenerative diseases, inflammatory pathologies, and cancer. MAGL expression is increased in invasive tumors, furnishing free fatty acids as pro-tumorigenic signals and for tumor cell growth. Here, a new class of benzylpiperidine-based MAGL inhibitors was synthesized, leading to the identification of 13, which showed potent reversible and selective MAGL inhibition. Associated with MAGL overexpression and the prognostic role in pancreatic cancer, derivative 13 showed antiproliferative activity and apoptosis induction, as well as the ability to reduce cell migration in primary pancreatic cancer cultures, and displayed a synergistic interaction with the chemotherapeutic drug gemcitabine. These results suggest that the class of benzylpiperidine-based MAGL inhibitors have potential as a new class of therapeutic agents and MAGL could play a role in pancreatic cancer.
2022
Bononi, G., Di Stefano, M., Poli, G., Ortore, G., Meier, P., Masetto, F., et al. (2022). Reversible monoacylglycerol lipase inhibitors: discovery of a new class of benzylpiperidine derivatives. JOURNAL OF MEDICINAL CHEMISTRY, 65(10), 7118-7140-7140 [10.1021/acs.jmedchem.1c01806].
File in questo prodotto:
File Dimensione Formato  
reversible-monoacylglycerol-lipase-inhibitors-discovery-of-a-new-class-of-benzylpiperidine-derivatives-Bononi-2022.pdf

accesso aperto

Descrizione: Articolo
Tipologia: PDF editoriale
Licenza: Creative commons
Dimensione 6.96 MB
Formato Adobe PDF
6.96 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/1209177